REFERENCES
1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al.. The
ROCKET AF Steering Committee . Rivaroxaban versus warfarin in
nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891
2. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H,
et al. Dabigatran versus warfarin in the treatment of acute venous
thromboembolism. N Engl J Med 2009; 361: 2342–2352.
3. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al.
Apixaban in comparison with warfarin in patients with atrial
fibrillation and Valvular heart disease: findings from the Apixaban for
reduction in stroke and other Thromboembolic events in atrial
fibrillation (ARISTOTLE) trial. Circulation. 2015;132(8):624–32
4. Craig T. January, et al. 2019 AHA/ACC/HRS Focused Update of the 2014
AHA/ACC/HRS Guideline for the Management of Patients with Atrial
Fibrillation: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines and the
Heart Rhythm Society in Collaboration with the Society of Thoracic
Surgeons. Circulation. 2019;140:e125–e151
5. Anderson E., Johnke K., Leedhal D., Glogoza M., Newman R., Dyke C.
Novel oral anticoagulants vs warfarin for the management of
postoperative atrial fibrillation: clinical outcomes and cost analysis.
J. Am Surg. 2015; 210(6):1095-1103.